Management Team

Nader Z. Pourhassan, PhD

Nader Z. Pourhassan, PhD

Director, President and CEO

Dr. Pourhassan received his Bachelor of Science from Utah State University in 1985, his Masters of Science from Brigham Young University in 1990 and his Ph.D. in Mechanical Engineering from the University of Utah in 1998. Dr. Pourhassan has authored three books.
His 20 years of business development experience set the stage for him to transform a publicly traded biotech company on the brink of bankruptcy, into a company on the cusp of potentially obtaining FDA approval for its first drug. If granted approval, the drug called leronlimab (PRO 140) could change the treatment paradigms in both HIV and metastatic cancer.
Dr. Pourhassan joined CytoDyn (CYDY) in 2008 as Chief Operating Officer and by September, 2012, was appointed President and CEO. He was responsible for identifying significant opportunities for leronlimab, and single handedly raised enough capital for CytoDyn to complete an acquisition of PRO 140 from Progenics Pharmaceuticals. Dr. Pourhassan has overseen the rapid preclinical and clinical developments of leronlimab (PRO 140) as a therapy for HIV, from Phase 2 development into successful completion of Phase 3 trials. This includes the oversight of the development of trial protocols and interaction with the U.S. Food and Drug Administration (FDA). Dr. Pourhassan also opened the door for exploring leronlimab (PRO 140) for other indications, most notably, he has been involved in the preclinical and clinical developments of leronlimab in indications for triple-negative breast cancer, colon cancer, GvHD, and NASH.
To advance the drug development of leronlimab, Dr. Pourhassan raised capital for CytoDyn of approximately $200 million over the last 5 years.

Richard G. Pestell, MD, PhD, MBA, FACP, FRS of Medicine, FRACP

Richard G. Pestell, MD, PhD, MBA, FACP, FRS of Medicine, FRACP

Vice Chairman, Chief Medical Officer

Richard is a clinician and researcher, who conducted clinical training in oncology and endocrinology. Dr Pestell's postdoctoral research was conducted at the Harvard School of Medicine and Massachusetts General Hospital (1991-1993). Dr Pestell holds a medical degree from the University of Western Australia, and an MD and Ph.D. from the University of Melbourne. He was inducted as a Fellow of the Royal Australian College of Physician, Fellow of the American College of Physicians and Fellow of the Royal Society of Medicine.

His past roles include Executive Vice President at Thomas Jefferson University (TJU has a $5.2B USD annual budget, 22,000 employees, and is located in Philadelphia USA). He was chairman of the Department of Oncology at Georgetown University and Associate Vice President of the Medical Center. As Director of the Sidney Kimmel Cancer Center (2005-2015) and Director of the Lombardi Cancer Center, Georgetown University (2002-2005) he was responsible for the oncology service line and oncology clinical trials and the interface with BioPharma.

He has received >$83M in research grant funding, has more than 700 published works including 44 book chapters, and reviews, is ranked in the world by Google Scholar (#1 cell cycle, #1 prostate cancer, #6 oncology) and received awards for his research discoveries (elected membership to ASCI (American Society of Clinical Investigation), Elected Member, Royal Society of Medicine, the RD Wright Medallion, Elected Fellow, American Association for the Advancement of Science, the Eric Susman Prize in Medicine, Advance Global Australian Award (Biotechnology), a Doctor of Medical Sciences, Honoris Causa, from the University of Melbourne, and awards from Susan G. Komen (Light of Life award, Jamie Brooke Lieberman Award).

Richard is a highly experienced Board Member and Executive with more than 20 years of experience in complex academic medical organizations. He has served on the advisory boards of USA National Cancer Institute-designated Cancer Centers, research institutes and foundations and international research institutes. Based upon his multiple issued patents, Richard was Founder and CEO of ProstaGene (sold to CytoDyn) and LightSeed.

Supplemental Biographical Information on Dr. Pestell:

Michael D. Mulholland

Michael D. Mulholland

Chief Financial Officer, Treasurer and Corporate Secretary

Mr. Mulholland brings to CytoDyn more than 25 years of senior level financial leadership for public companies in the business services, retail and manufacturing industries. His broad experience includes strategic planning, corporate finance, including raising debt and equity capital, acquisitions, corporate restructurings, SEC reporting, risk management, investor relations and corporate governance matters. In addition to his financial management experience, Mr. Mulholland has also managed IP-asset development for the chemical inventions of a leading European scientific inventor for improving human health, working with IP counsel to evaluate and prosecute domestic and foreign patent applications. Most recently, from 2011-2012, he served as Chief Financial Officer of Nautilus, Inc., a NYSE-listed developer and marketer of fitness equipment. He previously was Co-Chief Financial Officer of Corporate Management Advisors, Inc., a private holding company of various businesses and investments, including a majority interest in a publicly held manufacturing company, from 2010 to 2011; Vice President of Finance of Gevity HR, Inc., a former Nasdaq-listed professional employer organization, from 2008 to 2009; Chief Financial Officer and Secretary of Barrett Business Services, Inc., a Nasdaq-listed business services firm, from 1994 to 2008; and Executive Vice President, Chief Financial Officer and Secretary of Sprouse-Reitz Stores Inc., a former publicly held retail company, from 1988 to 1994. He began his career with Deloitte & Touche LLP. Mr. Mulholland received a B.S. in accounting and a M.B.A. in finance from the University of Oregon. He is a certified public accountant.

Nitya G. Ray, Ph.D.

Nitya G. Ray, Ph.D.

Chief Technology Officer - Head of Process Sciences, Manufacturing & Supply Chain

Dr. Ray rejoined CytoDyn in December 2018 and previously served as the company's Senior Vice President of Manufacturing from November 2015 to June 2017.  Most recently, Dr. Ray served as Executive Vice-President, Head of Product Development, Manufacturing and Supply Chain of Actinium Pharmaceuticals, Inc.  Prior to joining CytoDyn in 2015, Dr. Ray was Senior Vice President at Progenics Pharmaceuticals, Inc.  During his 14-year tenure at Progenics he was responsible for manufacturing, process & analytical sciences & quality control. He possesses extensive knowledge of leronlimab (PRO 140) development. Dr. Ray successfully manufactured the first 10 batches of leronlimab at Progenics under GMP, which was approved by the FDA for use in all clinical trials.

Dr. Ray’s return to CytoDyn brings 30 years of progressive, hands-on experience in strategic planning and execution of process development and manufacturing of biologics, engineered tissue therapeutics, antibody drug conjugates, and small molecule and radiopharmaceutical drugs.  He has demonstrated expertise in diverse technology platforms, product development, pre-clinical, clinical and commercial manufacturing, process and analytical sciences, quality control, global supply chain, quality systems and regulatory affairs.  Dr. Ray holds a Ph.D. in Biochemical Engineering and a M.S. degree in Chemical & Biochemical Engineering from Rutgers University and a B.S. degree in Chemical Engineering from Jadavpur University.

Brendan Rae, Ph.D., J.D.

Senior Vice President of Business Development

Dr. Rae is an accomplished licensing and business development executive with a proven track record of deal-making.  Dr. Rae comes to CytoDyn from Serina Therapeutics where he was Chief Business Officer, responsible for partnering, out licensing and overall company strategy.  Previously, Dr. Rae was the Executive Director of NPS Pharmaceuticals and Head of GI and Endocrinology Business Development until the acquisition by Shire Pharmaceuticals for $5.2 billion in 2015.  Prior to NPS, Dr. Rae held the role of Chief Business Officer at Arrowhead Research and Vivaldi Biosciences, as well as senior leadership roles at VIA Pharmaceuticals, Purdue Pharma and Hoffman-La Roche.  Prior to entering the biopharmaceutical industry, Dr. Rae was an attorney specializing in biopharmaceutical intellectual property law and, earlier in his career was a research scientist focusing on metastasis and the molecular basis of cellular transformation.  Dr. Rae holds a Juris Doctor degree from Seton Hall Law School and a Ph.D. in Virology from Glasgow University (Scotland) and completed a Postdoctoral Fellowship at the Roche Institute of Molecular Biology.     

George Bitar

Executive Director - Head of Quality

Mr. Bitar brings to CytoDyn over 25 years in quality management, technical operations, pharmaceutical manufacturing and R&D, including most recently as the Global Head of Quality at Hitachi Chemical Advanced Therapeutics Solutions, a cellular and gene therapy contract development and manufacturing organization.  Previously, Mr. Bitar led Pfizer’s generic oncology and biosimilars manufacturing through the approval process and was the Site Head of Quality for Pfizer’s specialty injectable and biologic drug products.  Prior to Pfizer, Mr. Bitar was Vice President – Head of Quality at InnoPharma Inc., which was acquired by Pfizer.   Mr. Bitar earned an M.S. in Pharmaceutical Chemistry with Honors from Seton Hall University and a B.Sc. in Chemical Biology (pre-med) with Honors from the Stevens Institute of Technology.